What is the Horizon Trial?
The Horizon Trial is a Phase 3 clinical research trial to test whether dimebon (latrepirdine) safely improves cognition (thinking and awareness) in patients with Huntington disease.
The Horizon Trial is being conducted as a collaboration between the Huntington Study Group (HSG) and the European Huntington's Disease Network (EHDN) under the sponsorship of Medivation and Pfizer.
What is dimebon (latrepirdine)?
Dimebon (latrepirdine) has a unique mechanism of action, distinct from currently available treatments. In preclinical studies, dimebon has been shown to protect brain cells from damage and enhance brain cell survival, potentially by stabilizing and improving mitochondrial function.
Join the Horizon Trial
Do you or does someone you care about have Huntington disease? If so, please consider taking part in this research trial. These 3 easy steps are all it takes to get started:
- Check locations of trial sites.
- Check the trial requirements.
- Call the HSG in North America at 800-487-7671 or the EHDN in Europe at +44 7791 985313 once you have completed steps 1 and 2.
It is important to check trial locations and understand the entry requirements before discussing the Horizon Trial with a physician.
